Insider Trading Activity For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Stephen Davis , CEO of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reportedly Sold 29,792 shares of the company’s stock at an average price of 40 for a total transaction amount of $1,191,680.00 SEC Form
Analyst Ratings History For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
- On 8/9/2018 JMP Securities Lower Price Target of rating Market Outperform to Market Outperform with a price target of $50.00 to $27.00
- On 11/16/2018 UBS Group Initiated Coverage of rating Neutral with a price target of $39.00
- On 5/31/2019 Raymond James Boost Price Target of rating Strong-Buy with a price target of $40.00 to $43.00
- On 7/31/2019 Bank of America Set Price Target of rating Buy with a price target of $31.00
- On 9/9/2019 Needham & Company LLC Boost Price Target of rating Buy with a price target of $34.00 to $60.00
- On 9/9/2019 Cowen Reiterated Rating Buy with a price target of $66.00
- On 9/9/2019 Piper Jaffray Companies Boost Price Target of rating Overweight with a price target of $35.00 to $56.00
Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 39.64 −0.88 2.17% with 39.34 shares trading hands.